Associated Papers
Nucleotide Substitution Biases in Related Cancer Driver Genes.
Khadre A et al.
International Journal of Molecular Sciences, 2025
Functional Analysis of Rare RAS Variants of Unknown Significance.
Park S et al.
Cancer Research Communications, 2025
KRAS G12C Inhibition in Solid Tumors: Biological Breakthroughs, Clinical Evidence, and Open Challenges.
Vitiello PP et al.
Cancers, 2025
Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors.
Riedl JM et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2025
Combination therapy of sotorasib and docetaxel overcomes resistance to sotorasib alone in KRAS G12C mutant lung adenocarcinoma.
Kuo CY et al.
Journal of Chemotherapy (florence, Italy), 2025
Performance and considerations in the use of diagnostic mutation panels for clonality testing in non-small-cell lung carcinoma.
Janssen J et al.
Esmo Open, 2025
Genomic Landscapes of Early-Onset Versus Average-Onset Colorectal Cancer Populations.
Storandt MH et al.
Cancers, 2025
KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies.
Liguori L et al.
Critical Reviews in Oncology/hematology, 2025
Genomic analysis of comprehensive next generation sequencing data to explore the criteria for MET amplification as an actionable biomarker in NSCLC.
Tsui DCC et al.
Lung Cancer (amsterdam, Netherlands), 2025
Comprehensive analysis of KRAS aberrations in pan-cancer, with a focus on prognostic and therapeutic implications.
Jung J et al.
Therapeutic Advances in Medical Oncology, 2025
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms.
Yang X et al.
Journal of Hematology & Oncology, 2024
Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity.
Kwon JJ et al.
Biorxiv : the Preprint Server for Biology, 2024
Clinical characteristics of KRAS mutation subtypes in non-small cell lung cancer population in Xinjiang, China, and their impact on the prognosis of immunotherapy.
Gu G et al.
Journal of Cancer Research and Clinical Oncology, 2024
KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways.
Mondal K et al.
Cells, 2024
Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations.
Fukuda K et al.
Cell Reports. Medicine, 2024
RASopathies are the most common set of monogenic syndromes identified by exome sequencing for nonimmune hydrops fetalis: A systematic review and meta-analysis.
Makhamreh MM et al.
American Journal of Medical Genetics. Part A, 2024
Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver.
Ros J et al.
International Journal of Molecular Sciences, 2024
Direct K-Ras Inhibitors to Treat Cancers: Progress, New Insights, and Approaches to Treat Resistance.
Nussinov R et al.
Annual Review of Pharmacology and Toxicology, 2024
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.
Desai J et al.
Nature Medicine, 2024
Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies.
Linehan A et al.
Frontiers in Medicine, 2024
Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer.
Chour A et al.
Frontiers in Oncology, 2024
Oncogenic KRAS effector USP13 promotes metastasis in non-small cell lung cancer through deubiquitinating β-catenin.
Guo Y et al.
Cell Reports, 2023
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia.
McCarter JGW et al.
Blood Advances, 2023
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.
Sacher A et al.
The New England Journal of Medicine, 2023
Beyond Structural Bioinformatics for Genomics with Dynamics Characterization of an Expanded KRAS Mutational Landscape.
Ratnasinghe BD et al.
Biorxiv : the Preprint Server for Biology, 2023
Genetics, Genomics and Emerging Molecular Therapies of Pancreatic Cancer.
Liu J et al.
Cancers, 2023
Targeting RAS mutants in malignancies: successes, failures, and reasons for hope.
Yang H et al.
Cancer Communications (london, England), 2023
The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation.
Jeong SY et al.
Therapeutic Advances in Gastroenterology, 2023
Beyond structural bioinformatics for genomics with dynamics characterization of an expanded KRAS mutational landscape.
Ratnasinghe BD et al.
Computational and Structural Biotechnology Journal, 2023
KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges.
Moldvay J et al.
Pathology Oncology Research : Por, 2023
Activating RAC1 variants in the switch II region cause a developmental syndrome and alter neuronal morphology.
Banka S et al.
Brain : a Journal of Neurology, 2022
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer.
Wang Z et al.
Molecular Biomedicine, 2022
Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
Bungaro M et al.
Current Treatment Options in Oncology, 2022
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.
Weiss A et al.
Cancer Discovery, 2022
Massively parallel phenotyping of coding variants in cancer with Perturb-seq.
Ursu O et al.
Nature Biotechnology, 2022
A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRASG12C inhibitors.
Feng S et al.
Proceedings of the National Academy of Sciences of the United States of America, 2022
Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance.
Reita D et al.
Cancers, 2022
Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.
Koga T et al.
Cancer Science, 2022
Targeting KRAS G12C mutation in lung adenocarcinoma.
Rohatgi A et al.
Lung Cancer (amsterdam, Netherlands), 2022
Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.
Vaclova T et al.
Scientific Reports, 2022
The path to the clinic: a comprehensive review on direct KRASG12C inhibitors.
Kwan AK et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2022
Understanding the influence of AMG 510 on the structure of KRASG12C empowered by molecular dynamics simulation.
Li Y et al.
Computational and Structural Biotechnology Journal, 2022